Olumiant from Lilly, Incyte clears third eczema study, but who will use it?

Months ago Incyte $INCY elected to stop funding the development of Olumiant (baricitinib) — coming up with those fundMonths ago Incyte $INCY elected to stop funding the development of Olumiant (baricitinib) — coming up with those funds became partner Eli Lilly’s problem. The JAK inhibitor, which has been dogged by safety concerns, has now cleared another late-stage atopic dermatitis (AD) study.s became partner Eli Lilly’s problem. The JAK inhibitor, which has been dogged by safety concerns, has now cleared another late-stage atopic dermatitis (AD) study.